Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BiomeBank faecal microbiota transplantation
- Development stage
- Unknown
- Lead developer
- BiomeBank
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Oral
01
Overview
BiomeBank faecal microbiota transplantation (brand name: BIOMICTRA) is a donor-derived, regulated microbiome-based therapy developed by the Australian biotechnology company BiomeBank. It consists of screened and processed human donor stool (faecal microbiota) suspended in sodium chloride and glycerol, and is frozen in a syringe-based formulation. BIOMICTRA is approved by Australia's Therapeutic Goods Administration (TGA) for the restoration of gut microbiota in the treatment of recurrent Clostridioides difficile infection (CDI), making it the world's first microbiome-based therapy regulated as a biological. It is administered via colonoscopy, enema, or nasogastric/nasoenteric tube. BiomeBank is also developing an oral capsule formulation (LYOMICTRA) and investigating the therapy under the Special Access Scheme and in clinical trials for other gastrointestinal disorders, including ulcerative colitis, Crohn's disease, irritable bowel syndrome, immune checkpoint inhibitor-induced enterocolitis, and functional constipation.
- Brand names
- BIOMICTRA
- Other names
- faecal microbiotafaecal microbiota (frozen)donor-derived faecal microbiota transplantationBiomeBank FMTBiomictra FMT
02
Targets
Dysbiotic gut microbial community in the colon
Beyond the preview
Go deeper on BiomeBank faecal microbiota transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BiomeBank faecal microbiota transplantation.